Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$2.84 -0.04 (-1.39%)
Closing price 04:00 PM Eastern
Extended Trading
$2.88 +0.04 (+1.58%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRA vs. JATT, MTVA, OKUR, ITRM, RENB, MAAQ, TENX, LEXX, DARE, and KZR

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include JATT Acquisition (JATT), MetaVia (MTVA), OnKure Therapeutics (OKUR), Iterum Therapeutics (ITRM), Renovaro (RENB), Mana Capital Acquisition (MAAQ), Tenax Therapeutics (TENX), Lexaria Bioscience (LEXX), Dare Bioscience (DARE), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Biomerica (NASDAQ:BMRA) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

22.3% of Biomerica shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 15.0% of Biomerica shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Biomerica's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company Overall Sentiment
Biomerica Neutral
JATT Acquisition Neutral

JATT Acquisition has a net margin of 0.00% compared to Biomerica's net margin of -93.64%. JATT Acquisition's return on equity of -49.58% beat Biomerica's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica-93.64% -98.97% -69.88%
JATT Acquisition N/A -49.58%2.84%

JATT Acquisition has lower revenue, but higher earnings than Biomerica.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$5.31M1.51-$4.97M-$2.32-1.22
JATT AcquisitionN/AN/A$6.85MN/AN/A

Summary

JATT Acquisition beats Biomerica on 6 of the 7 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.01M$2.52B$5.79B$10.49B
Dividend YieldN/A55.04%5.61%4.57%
P/E Ratio-1.2223.26348.8926.87
Price / Sales1.51563.63522.50164.46
Price / CashN/A27.8326.0131.15
Price / Book1.765.3615.536.51
Net Income-$4.97M$32.95M$3.29B$271.42M
7 Day Performance-5.02%3.96%200.87%3.68%
1 Month Performance-18.16%5.27%184.38%8.07%
1 Year Performance26.51%-0.72%325.51%29.68%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.2673 of 5 stars
$2.84
-1.4%
N/A+28.3%$8.01M$5.31M-1.2260Positive News
JATT
JATT Acquisition
N/A$1.92
-4.0%
N/A-55.2%$33.12MN/A0.003High Trading Volume
MTVA
MetaVia
1.7854 of 5 stars
$1.33
-11.3%
$7.50
+463.9%
N/A$32.19MN/A0.008Gap Down
High Trading Volume
OKUR
OnKure Therapeutics
2.7736 of 5 stars
$2.37
-0.8%
$32.33
+1,264.3%
N/A$32.07MN/A-0.49N/A
ITRM
Iterum Therapeutics
2.5207 of 5 stars
$0.68
-0.7%
$9.00
+1,224.9%
-36.5%$32.04MN/A-0.8010
RENB
Renovaro
0.4469 of 5 stars
$0.18
-4.0%
N/A-66.3%$31.50MN/A-0.2420Upcoming Earnings
MAAQ
Mana Capital Acquisition
N/A$3.79
-0.9%
N/A+1,325.0%$30.79MN/A0.001Gap Up
TENX
Tenax Therapeutics
2.5041 of 5 stars
$6.30
+3.4%
$18.00
+185.7%
+79.6%$28.73MN/A-6.859High Trading Volume
LEXX
Lexaria Bioscience
3.2719 of 5 stars
$1.46
+12.3%
$4.00
+174.0%
-62.0%$28.56M$615.92K-2.187Positive News
DARE
Dare Bioscience
2.1104 of 5 stars
$2.10
+3.4%
$10.00
+376.2%
-35.0%$28.31M$10K-0.9830Positive News
KZR
Kezar Life Sciences
3.7552 of 5 stars
$3.75
-4.1%
$9.00
+140.0%
-34.1%$27.46MN/A-0.3960Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners